Despite these criteria, hypercalcemia in the absence of other clinical or laboratory features of an MPN has become a periodic, if infrequent prompt for molecular testing of the BCR-ABL1 fusion and/or the JAK2 V617F. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.